Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Esperion Therapeutics, Inc.
< Previous
1
2
Next >
Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update
August 12, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 07, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Report Second Quarter 2024 Financial Results on August 12
July 25, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Participate in Upcoming BTIG Biotech Conference
July 24, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries
July 16, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility
June 28, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Participate in Upcoming June Investor Conferences
May 23, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk
May 22, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia
May 20, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®
May 14, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 10, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Reports First Quarter 2024 Financial Results
May 07, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Participate in Upcoming May Investor Conferences
April 29, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Report First Quarter 2024 Financial Results on May 7
April 23, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity
April 07, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024
April 01, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference
March 26, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24
March 25, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
March 22, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events
March 22, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Reports Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
February 16, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27
February 13, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
RFK, Esperion Therapeutics Announce 2024 Promotional Schedule
February 01, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
January 23, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Announces Pricing of $85.1 Million Public Offering of Common Stock
January 18, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Announces Proposed Public Offering of Common Stock
January 18, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation
January 03, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Participate in 42nd Annual J.P. Morgan Healthcare Conference
December 18, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
U.S. FDA Updates LDL-C Lowering Indication for Esperion’s NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet
December 13, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.